As of 12:43pm ET
| +0.13 / +0.82%|
Fresenius SE & Co. KGaA engages in the provision of healthcare related products and services. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate/Other. The Fresenius Medical Care segment provides dialysis products and services for patients with chronic kidney failure. The Fresenius Kabi segment offers IV drugs including intravenously administered generic anesthetics, anti-infectives, analgesics, and drugs for the treatment of oncological and other critical diseases; and infusion solutions and blood volume substitutes for infusion therapy. The Fresenius Helios segment operates hospitals. The Fresenius Vamed segment manages projects and provides services for hospitals and other healthcare facilities. The Corporate/Other segment comprises the holding activities of the company and the activities of the information technology service provider Fresenius Netcare. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.
|Ulf Mark Schneider||Chairman-Management Board, President & CEO|
|Stephan Sturm||Chief Financial Officer|
|JÃ¼rgen GÃ¶tz||Chief Legal & Compliance Officer|
|Francesco de Meo||Member-Management Board|